Objective: To describe the prevalence and to assess type and indicators of hormone replacement therapy (HRT) use in the two German EPIC-cohorts.
Methods: Approximately 30,000 women predominantly aged 35-65 years were recruited in EPIC-Heidelberg and EPIC-Potsdam between 1994 and 1998. Information on diet and lifestyle, medical history and use of hormone therapy was collected at recruitment. Prevalence and type of HRT-regime was described and logistic regression models used to examine correlates of HRT-use.
Results: Among women aged 45-64 years, 37.9% in Heidelberg and 35.8% in Potsdam were current HRT users. Among current users without bilateral oophorectomy, 40.5% in Heidelberg and 23.7% in Potsdam used HRT for at least 5 years. Most women in Heidelberg were taking cyclic combined or estrogen monotherapy, whereas in Potsdam both continuous combined and cyclic combined therapies were most frequently used. In both centres, older age, ever use of oral contraceptives, and alcohol consumption were indicators for both current and ever HRT-use. HRT-use was less frequent in obese women as compared to women with lower BMI. In Potsdam, but not in Heidelberg, higher education and current smoking were associated with HRT-use.
Conclusion: In both German EPIC-cohorts, the prevalence of medication with HRT is high compared to other European countries. Types of exogenous hormones used differed by centre. Various reproductive and lifestyle characteristics were identified as correlates of HRT-use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.maturitas.2006.11.008 | DOI Listing |
Background: It is essential that both drug and lifestyle-based interventions aimed at delaying the functional decline in conditions like Alzheimer's disease and related dementias (ADRDs) capture change in functioning that incorporates the person's voice. Such brain health priorities can vary across populations and it is unclear to what degree findings from the ePSOM program in the UK might apply to the US.
Methods: We conducted an online nationwide study to understand what matters to people aged 50 and older about their brain health in the US.
Alzheimers Dement
December 2024
Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
The most recent Alzheimer's clinical trials, including those which reported successful outcomes, use neuroimaging biomarkers of both amyloid and tau for screening participants and demonstrating a treatment effect on pathology. Some of these trials, notably Lecanemab, hint at a potential sex bias in treatment outcome, alluding to major implications for clinical practice when recommending treatment options. Sex differences in treatment response are not surprising given that women are at greater risk of progression to AD dementia, particularly if they carry APOEe4.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA.
Background: Studies link nature exposure to better cognitive health outcomes. However, little is known about which types or 'how much' of nature is needed for health benefits. Studies often lack diverse aging populations and have small sample sizes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Unitiy Hospital, Rochester, NY, USA.
Background: Psychotropic drug prescriptions are commonly used to manage behavioral and psychological symptoms of dementia in elderly patients in long-term care facilities. The prevalence of psychotropic drug use in this population raises concerns due to potential side effects, polypharmacy and quality of life of the patients.
Aim: To assess the trends in psychotropic drug prescriptions for elderly patients with dementia following the continuous implementation of multimodal comprehensive care communication skills training for staff in a long-term care hospital.
Alzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA.
Background: In the United States, Black people represent 12% of the total US population and account for 19.3% of dementia cases. Social determinants of health (SDOH) and vascular comorbidities contribute to Black/African Americans having a higher risk of Alzheimer's disease and related dementias (ADRD).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!